Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04448145 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence

Study acronym: C-PIC
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Sep 2026 → Aug 2027
See other at-risk trials from Columbia University

Record History

  1. Primary and study completion pushed from Sep 2026 to Aug 2027 Primary endpoints: details revised at 2 of 8 entries · Eligibility criteria expanded, about 6 words · Publications: details revised at 14 of 16 entries Show 3 more changesShow less
    • Primary endpoints: details revised at 2 of 8 entries
    • Eligibility criteria expanded, about 6 words
    • Publications: details revised at 14 of 16 entries
  2. Primary and study completion dates: Oct 2025 to Sep 2026v8
  3. Primary and study completion dates: Dec 2024 to Oct 2025v7
  4. Enrollment target: 325 to 800 Primary and study completion dates: May 1, 2024 to Dec 2024 · Study title expanded, about 4 wordsv6 Show 2 more changesShow less
    • Primary and study completion dates: May 1, 2024 to Dec 2024
    • Study title expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  5. Primary and study completion dates: May 1, 2022 to May 1, 2024v5
Show 3 earlier versionsHide 3 earlier versions
  1. Re-verified, no change to tracked fieldsv4
  2. Study description revised Eligibility criteria expanded, about 3 wordsv3 Show 1 more changeShow less
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Primary and study completion dates: Mar 1, 2021 to May 1, 2022 Enrollment target: 250 to 325 · Eligibility criteria expanded, about 8 words · Study arms: 1 to 2v2 Show 3 more changesShow less
    • Enrollment target: 250 to 325
    • Eligibility criteria expanded, about 8 words
    • Study arms: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The 2019-2020 COVID-19 pandemic is the largest outbreak in recent history. It is not known how long after someone gets sick with COVID-19 and recovers that they can still infect other people. It is also not known how quickly people make antibodies against the virus, which help clear infection from the body. The investigators will enroll 300 people who had COVID-19 based on lab testing or confirmed exposure to participate. An additional 25 participants who have never tested positive for COVID and have not had the vaccine will be enrolled as negative controls. Participants will complete a survey at enrollment. The investigators will also collect blood, nose swab, saliva, stool, semen, and breast milk to test for the virus. The investigators will ask participants to complete a survey and give specimens up to 12 times over 24 months. This information will be used to study how long the virus can live in different parts of the body, antibody development, and post-infectious complications. The investigators hope that this information will allow medical and public health providers to make recommendations to better care for patients in the convalescent phase of COVID-19 infection.
Trial Details
NCT Number NCT04448145
Lead Sponsor Columbia University
Conditions COVID-19, Corona Virus Infection, SARS-CoV 2
Enrollment 800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov